Latest Breaking News On - Secondary endpoints - Page 1 : comparemela.com

Dermavant Sciences: Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA (tapinarof) cream, 1% for Adults and Children 2 Years of Age and Older with Atopic Dermatitis in JAAD

- ADORING 1 and ADORING 2 met their primary efficacy endpoints and all secondary endpoints - - ADORING 1 and ADORING 2 data were included in the sNDA filing for VTAMA cream, 1% in atopic dermatitis

United statesEli lillyAngela salerno robinPhilipm brownLinkedin dermavant sciencesRoivant sciencesDermavant sciences gmbJournal of the american academy dermatologyDermavant sciences incDermavant sciencesAmerican academyChief medical officerSecondary endpointsPrescribing informationAll rightsVice president

Neurosense Therapeutics (NRSN) Reports Positive Data Validating Phase 2b Topline Readout

Neurosense Therapeutics (NRSN) Reports Positive Data Validating Phase 2b Topline Readout
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSeanm healeyAmerican academy of neurologyAmerican academy of neurology annual meetingNeurosense therapeutics ltdNeurosense therapeuticsEmerging scienceLate breakerAmerican academyNeurology annual meetingAmyotrophic lateral sclerosisMeets primarySecondary endpointsMassachusetts general

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomColorado convention centerPrnewswire neurosense therapeutics ltdAmerican academy of neurology annual meetingExchange commissionNeurosense therapeutics ltdEmerging scienceLate breaker equivalentTime highlights phaseSense therapeuticsMassachusetts general hospitalDorn professorHarvard medical schoolLate breakerAmerican academy

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomPuerto ricoSan diegoFrance generalJessica akopyanJustin claeysKate meyerLoretta fiorilloCallis duffinPonda motsepe ditshegoMelinda gooderhamJolla institute for immunologyChemocentryx incTeneobio incAmerican academy of dermatology

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
bubblear.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bubblear.com Daily Mail and Mail on Sunday newspapers.

United statesPuerto ricoUnited kingdomSan diegoFrance generalJessica akopyanLoretta fiorilloMelinda gooderhamKate meyerCallis duffinPonda motsepe ditshegoJustin claeysAmerican academy of dermatologyDrug administrationWorld best companiesNational psoriasis foundation